Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

Withdrawn before enrolling · Phase 1

Conditions studied: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer

In brief

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for gastrointestinal cancer. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have gastrointestinal cancer.

Key facts

Study ID

NCT00025532

Run by

University of California, San Francisco

People needed

0

Starts

2001-04-01

Last updated by the study team

2012-09-14

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.